Amgen and Horizon resolve FTC lawsuit; consent order clears path to close acquisition in early Q4 2023

AMGEN INC

Consent order agreement with FTC resolves pending administrative lawsuit related to Amgen's acquisition of Horizon.
Parties will jointly file to dismiss preliminary injunction motion and dissolve TRO in U.S. District Court for Northern District of Illinois.
Amgen gave narrow assurance it has no intention or ability to bundle Horizon's TEPEZZA or KRYSTEXXA; no impact on business.
Acquisition expected to close in early Q4 2023, pending final approvals under Irish law.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.